Oncotarget

Research Perspectives:

Targeting cancer with peptide aptamers

PDF  |  Full Text  |  How to cite

Oncotarget. 2011; 2:557-561. https://doi.org/10.18632/oncotarget.297

Metrics: PDF 3882 views  |  Full Text 7075 views

Renaud Seigneuric1,2, Jessica Gobbo1,2, Pierre Colas3, Carmen Garrido1,2

1Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France

2Université de Bourgogne, Dijon, France

3CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France

Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011;

Correspondence:

Renaud Seigneuric, email:

Abstract

A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.